Brief: Ideaya Announces Development Candidate Nomination Of Ide251
16/12/2024 12:10
Dec 16 (Reuters) - IDEAYA Biosciences Inc IDYA.O :
* IDEAYA ANNOUNCES DEVELOPMENT CANDIDATE NOMINATION OF
IDE251, A
POTENTIAL FIRST-IN-CLASS KAT6/7 DUAL INHIBITOR TARGETING 8P11
AMPLIFICATION TUMORS IN BREAST AND LUNG CANCERS
* IDEAYA BIOSCIENCES INC: TARGETING IND SUBMISSION FOR
IDE251 IN
2025
Source text: ID:nPn9WYll1a
Further company coverage: IDYA.O
Recent news on IDEAYA Biosciences
See all newsBrief: Ideaya Biosciences And Servier Announce Data From Three Clinical Trials At Esmo 2026 Supporting The Potential Of Darovasertib To Become A Foundational New Therapy For Patients Across The Treatment Journey Of Uveal Melanoma
Brief: Ideaya Biosciences Announces The Promotion Of Dr. Michael White To President, Research And Development
Brief: Ideaya Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Ideaya Biosciences Inc Reports Results For The Quarter Ended June 30: Earnings Summary
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj